PharmaTher Holdings (CNSX:PHRM) - Hisse Senedi Fiyatı, Haberler ve Analizler

PHRM Stoklara Genel Bakış

PHRM temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( CA$0 )

1 yıldan az nakit akışı var

Kazançlar son 5 yılda yılda 40.8% oranında azaldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 1 daha fazla risk

PharmaTher Holdings Ltd. Rakipler

Devonian Health Group

TSXV:GSD

CA$21.5m

Chalice Brands

CNSX:CHAL

CA$19.0m

Rubicon Organics

TSXV:ROMJ

CA$18.1m

Numinus Wellness

TSX:NUMI

CA$17.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti PharmaTher Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.24
52 Haftanın En Yüksek Seviyesi	CA$0.43
52 Haftanın En Düşük Seviyesi	CA$0.14
Beta	3.41
11 Aylık Değişim	14.29%
3 Aylık Değişim	33.33%
1 Yıllık Değişim	45.45%
33 Yıllık Değişim	-29.41%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	23.08%

Son Haberler & Güncellemeler

Recent updates

Here's Why We're Not Too Worried About PharmaTher Holdings' (CSE:PHRM) Cash Burn Situation

Dec 31

Hissedar Getirileri

	PHRM	CA Pharmaceuticals	CA Pazar
7D	14.3%	1.7%	0.3%
1Y	45.5%	-20.7%	23.0%

Getiri vs. Endüstri: PHRM geçen yıl % -20.7 oranında getiri sağlayan Canadian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: PHRM geçen yıl % 23 oranında getiri sağlayan Canadian Piyasasını aştı.

Fiyat Oynaklığı

Is PHRM's price volatile compared to industry and market?
PHRM volatility
PHRM Average Weekly Movement	20.1%
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: PHRM hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PHRM 'nin haftalık oynaklığı ( 20% ) geçen yıl boyunca sabit kaldı, ancak hala Canadian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2019	n/a	Fabio Chianelli	www.pharmather.com

Özel bir ilaç şirketi olan PharmaTher Holdings Ltd., hasta sonuçlarını iyileştirmek için yeni dağıtım yöntemlerini benimseyen ve bunlara izin veren özel ilaçlar geliştirmekte ve ticarileştirmektedir. Şirketin ürün portföyünde Parkinson hastalığı, Amyotrofik Lateral Skleroz, kompleks bölgesel ağrı ve anestezi ve prosedürel sedasyon tedavisi için ketamin hidroklorür enjeksiyonu olan KETARX bulunmaktadır. Ruh sağlığı, nörolojik ve ağrı bozuklukları için bir mikroiğne yaması olan KETARX'ı ve teşhis ve cerrahi prosedürler için genel anestezinin sürdürülmesi için KETARX On-body pompasını geliştirmektedir.

PharmaTher Holdings Ltd. Temel Bilgiler Özeti

PharmaTher Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PHRM temel i̇stati̇sti̇kler
Piyasa değeri	CA$23.01m
Kazançlar(TTM)	-CA$2.16m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-9.8x

F/K Oranı

PHRM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PHRM gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$2.16m
Kazançlar	-CA$2.16m

Son Raporlanan Kazançlar

Aug 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.024
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

PHRM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PHRM Stoklara Genel Bakış

Risk Analizi

PharmaTher Holdings Ltd. Rakipler

TSXV:GSD

CA$21.5m

CNSX:CHAL

CA$19.0m

TSXV:ROMJ

CA$18.1m

TSX:NUMI

CA$17.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd. Announces Update on FDA New Drug Application for Ketamine

PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

New major risk - Share price stability

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

Recent updates

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd. Announces Update on FDA New Drug Application for Ketamine

PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

New major risk - Share price stability

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine

Here's Why We're Not Too Worried About PharmaTher Holdings' (CSE:PHRM) Cash Burn Situation

New major risk - Financial position

PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

New major risk - Market cap size

PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings Ltd. Initiates Filing of Abbreviated New Drug Application for KETARX to the FDA

PharmaTher Holdings Ltd. Announces FDA Approval for KETARX

PharmaTher Holdings Ltd. Submits FDA Meeting Package to Discuss 505(B)(2) Pathway for New Drug Application of Ketarx (Ketamine) On-Body Pump System

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX (Ketamine) in Parkinson's Disease

PharmaTher Holdings Ltd. Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

High number of new and inexperienced directors

Pharmather Holdings Ltd. Announces A Poster Presentation of the Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’S Disease

High number of new and inexperienced directors

PharmaTher Holdings Ltd. to Present Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease At the MDS International Congress of Parkinson's Disease and Movement Disorders

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

PharmaTher Holdings Ltd. Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketarx Ketamine Patch

PharmaTher Holdings Ltd Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

PharmaTher Holdings Ltd. Announces Positive Results from Study for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Announces Positive Results from Study of Ketabet™ for Depression

PharmaTher Holdings Ltd. Announces FDA Approval of Investigational New Drug Application for Ketamine to Treat ALS

PharmaTher Holdings Ltd. Announces Publication of Research Data for Ketabet™

PharmaTher Holdings Ltd Provides Product Pipeline Update and Expected Milestones for 2022

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings Ltd. announced that it expects to receive CAD 10 million in funding

Pharmather Holdings Ltd. Provides Product Pipeline Update

PharmaTher Holdings Ltd. Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Holdings Ltd. Files FDA Pre-IND Meeting Request and Briefing Package for KETABET™ to Treat Depression

Pharmather Holdings Ltd. Provides Research and Development Update and Milestones for 2021

Pharmather Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Announces FDA Approval of Ketamine IND in the Treatment of Parkinson’s Disease

PharmaTher Holdings Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

New 90-day low: CA$0.24

PharmaTher Inc. Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

Newscope Capital Corporation Announces Successful Completion of a Type B Pre-Investigational New Drug

New 90-day high: CA$0.41

Revive Therapeutics Ltd. Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Pharmather Inc. Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson's Disease

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

PharmaTher Holdings Ltd. Temel Bilgiler Özeti

0.0x

-9.8x

Kazanç ve Gelir